PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
33184849-3	2021	The progression of NAFLD and insulin resistance was reversed by GW6471 a small-molecule antagonist of peroxisome proliferator-activated receptor alpha (PPARalpha).	GW 6471	64-70	peroxisome proliferator activated receptor alpha	Mus musculus	102-150
33184849-3	2021	The progression of NAFLD and insulin resistance was reversed by GW6471 a small-molecule antagonist of peroxisome proliferator-activated receptor alpha (PPARalpha).	GW 6471	64-70	peroxisome proliferator activated receptor alpha	Mus musculus	152-161
33829414-10	2021	Moreover, these in vivo neuroprotective effects of OEA were mediated by the PPARalpha receptor, as pretreatment with the PPARalpha antagonist GW6471 (2.5 mg/kg, i.p.)	GW 6471	142-148	peroxisome proliferator activated receptor alpha	Mus musculus	76-85
33959154-7	2021	The findings also revealed that the PPARalpha antagonist GW6471 can lower cell viability and induce autophagy in the 786-O ccRCC cell line.	GW 6471	57-63	peroxisome proliferator activated receptor alpha	Homo sapiens	36-45
33472092-16	2021	Interestingly, the addition of the PPARalpha inhibitor GW6471 abolished the beneficial effects of PNS.	GW 6471	55-61	peroxisome proliferator activated receptor alpha	Rattus norvegicus	35-44
33508418-3	2021	Meanwhile, the peroxisome proliferator activated receptor (PPARalpha) blocker, GW6471, with the Adenosine 5"-monophosphate (AMP)-activated protein kinase (AMPK) activator, AICAR, were applied in vitro study to clarify the role of PPARalpha/SREBP-1c/FAS/GPAT/AMPK signal pathway in the process.	GW 6471	79-85	peroxisome proliferator activated receptor alpha	Homo sapiens	59-68
33525605-0	2021	PPARalpha-Selective Antagonist GW6471 Inhibits Cell Growth in Breast Cancer Stem Cells Inducing Energy Imbalance and Metabolic Stress.	GW 6471	31-37	peroxisome proliferator activated receptor alpha	Homo sapiens	0-9
33508418-3	2021	Meanwhile, the peroxisome proliferator activated receptor (PPARalpha) blocker, GW6471, with the Adenosine 5"-monophosphate (AMP)-activated protein kinase (AMPK) activator, AICAR, were applied in vitro study to clarify the role of PPARalpha/SREBP-1c/FAS/GPAT/AMPK signal pathway in the process.	GW 6471	79-85	5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase	Homo sapiens	172-177
33424957-6	2020	In addition, we also found that PPARalpha is the target gene of microRNA-21; PPARalpha antagonist GW6471 could reverse the effect of antagomir-21.	GW 6471	98-104	peroxisome proliferator activated receptor alpha	Mus musculus	32-41
32504066-12	2021	Furthermore, addition of PPARalpha antagonist GW6471 (10 muM) partially abolished the anti-hypertrophic effects and metabolic effects of puerarin in NRCM.	GW 6471	46-52	peroxisome proliferator activated receptor alpha	Rattus norvegicus	25-34
33424957-6	2020	In addition, we also found that PPARalpha is the target gene of microRNA-21; PPARalpha antagonist GW6471 could reverse the effect of antagomir-21.	GW 6471	98-104	microRNA 21a	Mus musculus	64-75
33424957-6	2020	In addition, we also found that PPARalpha is the target gene of microRNA-21; PPARalpha antagonist GW6471 could reverse the effect of antagomir-21.	GW 6471	98-104	peroxisome proliferator activated receptor alpha	Mus musculus	77-86
32020589-9	2020	Moreover, PUFA-induced vasculogenesis was blunted by the PPAR-alpha inhibitor GW6471.	GW 6471	78-84	peroxisome proliferator activated receptor alpha	Mus musculus	57-67
33246954-7	2020	PPARalpha-specific antagonist GW6471 abolishes the effect of BMP9 knockdown.	GW 6471	30-36	peroxisome proliferator activated receptor alpha	Mus musculus	0-9
33246954-7	2020	PPARalpha-specific antagonist GW6471 abolishes the effect of BMP9 knockdown.	GW 6471	30-36	growth differentiation factor 2	Mus musculus	61-65
32470546-4	2020	Dual-luciferase reporter assays and primary hepatocyte studies demonstrated that the peroxisome proliferator-activated receptor alpha (PPARalpha) signaling mediated the protective effect of celastrol, which was not observed in Ppara-null mice, and co-treatment of wild-type mice with the PPARalpha antagonist GW6471.	GW 6471	309-315	peroxisome proliferator activated receptor alpha	Mus musculus	85-133
33119975-14	2020	The PPAR-alpha agonist WY 14643 protects the NANC inhibitory system of the guinea pig trachea from the effect of inhaled ammonium persulphate and its protective effect is antagonized by GW 6471.	GW 6471	186-193	peroxisome proliferator-activated receptor alpha	Cavia porcellus	4-14
32621919-11	2020	Blocking PPARalpha expression using the PPARalpha inhibitor GW6471 reversed the functional influence of TRIB3 on AML cells.	GW 6471	60-66	peroxisome proliferator activated receptor alpha	Homo sapiens	9-18
32621919-11	2020	Blocking PPARalpha expression using the PPARalpha inhibitor GW6471 reversed the functional influence of TRIB3 on AML cells.	GW 6471	60-66	peroxisome proliferator activated receptor alpha	Homo sapiens	40-49
32621919-11	2020	Blocking PPARalpha expression using the PPARalpha inhibitor GW6471 reversed the functional influence of TRIB3 on AML cells.	GW 6471	60-66	tribbles pseudokinase 3	Homo sapiens	104-109
32470546-4	2020	Dual-luciferase reporter assays and primary hepatocyte studies demonstrated that the peroxisome proliferator-activated receptor alpha (PPARalpha) signaling mediated the protective effect of celastrol, which was not observed in Ppara-null mice, and co-treatment of wild-type mice with the PPARalpha antagonist GW6471.	GW 6471	309-315	peroxisome proliferator activated receptor alpha	Mus musculus	135-144
32549364-7	2020	These effects of ALS-L1023 were comparable to those of the PPARalpha ligand fenofibrate, while the PPARalpha antagonist GW6471 inhibited the actions of ALS-L1023 on lipid accumulation and PPARalpha luciferase activity in HepG2 cells.	GW 6471	120-126	peroxisome proliferator activated receptor alpha	Homo sapiens	99-108
32416448-9	2020	PPARalpha inhibitor GW6471 treatment or knockdown of PPARalpha using lentivirus-expressing shRNA inhibited the PC-induced increase in the protein expression of UCP1, PGC-1alpha and PRDM16 in C3H10T1/2 pluripotent stem cells and 3T3-L1 adipocytes, indicating the potential role of PPARalpha in PC-mediated brown-like adipocyte formation.	GW 6471	20-26	peroxisome proliferator activated receptor alpha	Mus musculus	0-9
32416448-9	2020	PPARalpha inhibitor GW6471 treatment or knockdown of PPARalpha using lentivirus-expressing shRNA inhibited the PC-induced increase in the protein expression of UCP1, PGC-1alpha and PRDM16 in C3H10T1/2 pluripotent stem cells and 3T3-L1 adipocytes, indicating the potential role of PPARalpha in PC-mediated brown-like adipocyte formation.	GW 6471	20-26	uncoupling protein 1 (mitochondrial, proton carrier)	Mus musculus	160-164
32416448-9	2020	PPARalpha inhibitor GW6471 treatment or knockdown of PPARalpha using lentivirus-expressing shRNA inhibited the PC-induced increase in the protein expression of UCP1, PGC-1alpha and PRDM16 in C3H10T1/2 pluripotent stem cells and 3T3-L1 adipocytes, indicating the potential role of PPARalpha in PC-mediated brown-like adipocyte formation.	GW 6471	20-26	peroxisome proliferative activated receptor, gamma, coactivator 1 alpha	Mus musculus	166-176
32416448-9	2020	PPARalpha inhibitor GW6471 treatment or knockdown of PPARalpha using lentivirus-expressing shRNA inhibited the PC-induced increase in the protein expression of UCP1, PGC-1alpha and PRDM16 in C3H10T1/2 pluripotent stem cells and 3T3-L1 adipocytes, indicating the potential role of PPARalpha in PC-mediated brown-like adipocyte formation.	GW 6471	20-26	PR domain containing 16	Mus musculus	181-187
32549364-7	2020	These effects of ALS-L1023 were comparable to those of the PPARalpha ligand fenofibrate, while the PPARalpha antagonist GW6471 inhibited the actions of ALS-L1023 on lipid accumulation and PPARalpha luciferase activity in HepG2 cells.	GW 6471	120-126	peroxisome proliferator activated receptor alpha	Homo sapiens	99-108
32307816-8	2020	Treatment of PFOA mice with the PPARalpha antagonist GW6471 or the FGF21 inhibitor PD173074 rescued SCN vasopressin and AVPV-kisspeptin expression.	GW 6471	53-59	peroxisome proliferator activated receptor alpha	Mus musculus	32-41
32595495-6	2020	Antagonist GW9662 decreased the mRNA expression of Ppargamma and target genes Adpn and Glut4 whereas GW6471 decreased the mRNA expression of Pparalpha and target genes Cpt-1alpha, Lpl, Mcad, Lcad, Acox1, etc.	GW 6471	101-107	peroxisome proliferator activated receptor alpha	Rattus norvegicus	141-150
32595495-6	2020	Antagonist GW9662 decreased the mRNA expression of Ppargamma and target genes Adpn and Glut4 whereas GW6471 decreased the mRNA expression of Pparalpha and target genes Cpt-1alpha, Lpl, Mcad, Lcad, Acox1, etc.	GW 6471	101-107	carnitine palmitoyltransferase 1A	Rattus norvegicus	168-178
32595495-6	2020	Antagonist GW9662 decreased the mRNA expression of Ppargamma and target genes Adpn and Glut4 whereas GW6471 decreased the mRNA expression of Pparalpha and target genes Cpt-1alpha, Lpl, Mcad, Lcad, Acox1, etc.	GW 6471	101-107	lipoprotein lipase	Rattus norvegicus	180-183
32307816-8	2020	Treatment of PFOA mice with the PPARalpha antagonist GW6471 or the FGF21 inhibitor PD173074 rescued SCN vasopressin and AVPV-kisspeptin expression.	GW 6471	53-59	KiSS-1 metastasis-suppressor	Mus musculus	125-135
32189072-8	2020	PPARalpha agonists fenofibrate and WY-14643 suppressed, whereas PPARalpha antagonist GW6471 and siRNA-mediated knockdown of PPARalpha induced Fgf23 gene expression.	GW 6471	85-91	peroxisome proliferator activated receptor alpha	Rattus norvegicus	64-73
32326173-10	2020	Moreover, the inhibitory effect of FXOH on NO induction was significantly abolished by the peroxisome proliferator-activated receptor alpha (PPAR-alpha) inhibitor GW6471.	GW 6471	163-169	peroxisome proliferator activated receptor alpha	Mus musculus	91-139
32326173-10	2020	Moreover, the inhibitory effect of FXOH on NO induction was significantly abolished by the peroxisome proliferator-activated receptor alpha (PPAR-alpha) inhibitor GW6471.	GW 6471	163-169	peroxisome proliferator activated receptor alpha	Mus musculus	141-151
31809938-5	2020	The numbers of secondary, early antral and antral follicles were reduced in PFBS-mice with an increase in the atretic follicles, and these changes were recovered by the replacement of L-thyroxinein or the treatment with PPARalpha antagonist GW6471.	GW 6471	241-247	peroxisome proliferator activated receptor alpha	Mus musculus	220-229
32189072-8	2020	PPARalpha agonists fenofibrate and WY-14643 suppressed, whereas PPARalpha antagonist GW6471 and siRNA-mediated knockdown of PPARalpha induced Fgf23 gene expression.	GW 6471	85-91	peroxisome proliferator activated receptor alpha	Rattus norvegicus	64-73
32189072-8	2020	PPARalpha agonists fenofibrate and WY-14643 suppressed, whereas PPARalpha antagonist GW6471 and siRNA-mediated knockdown of PPARalpha induced Fgf23 gene expression.	GW 6471	85-91	fibroblast growth factor 23	Rattus norvegicus	142-147
31981312-7	2020	PPARalpha antagonists, GW6471 and MK886, could significantly inhibit the furanone-induced lipid-lowering effect.	GW 6471	23-29	peroxisome proliferator activated receptor alpha	Homo sapiens	0-9
31794424-9	2020	In human G cells, the PPAR-alpha agonist FFB increased gastrin protein expression that was blocked by GW6471, a PPAR-alpha antagonist, and LE300, a D1-like receptor antagonist.	GW 6471	102-108	peroxisome proliferator activated receptor alpha	Homo sapiens	22-32
31794424-9	2020	In human G cells, the PPAR-alpha agonist FFB increased gastrin protein expression that was blocked by GW6471, a PPAR-alpha antagonist, and LE300, a D1-like receptor antagonist.	GW 6471	102-108	gastrin	Homo sapiens	55-62
31794424-9	2020	In human G cells, the PPAR-alpha agonist FFB increased gastrin protein expression that was blocked by GW6471, a PPAR-alpha antagonist, and LE300, a D1-like receptor antagonist.	GW 6471	102-108	peroxisome proliferator activated receptor alpha	Homo sapiens	112-122
30945071-10	2019	GW6471 (a PPARalpha antagonist) significantly reversed the anti-nociceptive effects of PEA but not those of HU210 or WIN55, 212.	GW 6471	0-6	peroxisome proliferator activated receptor alpha	Rattus norvegicus	10-19
32248343-5	2020	However, inhibition of lipid oxidation using GW9662 (an inhibitor of PPAR-gamma) and GW6471 (an inhibitor of PPAR-alpha) abolished the anti-inflammatory effect of PPC.	GW 6471	85-91	peroxisome proliferator activated receptor alpha	Mus musculus	109-119
31499122-9	2019	The PPARalpha antagonist GW6471 reversed the inhibitory effect of DHA on TNFalpha-induced ICAM-1 expression, p65 nuclear translocation, NFkappaB and DNA binding activity, and THP-1 cell adhesion.	GW 6471	25-31	peroxisome proliferator activated receptor alpha	Homo sapiens	4-13
31499122-9	2019	The PPARalpha antagonist GW6471 reversed the inhibitory effect of DHA on TNFalpha-induced ICAM-1 expression, p65 nuclear translocation, NFkappaB and DNA binding activity, and THP-1 cell adhesion.	GW 6471	25-31	tumor necrosis factor	Homo sapiens	73-81
31499122-9	2019	The PPARalpha antagonist GW6471 reversed the inhibitory effect of DHA on TNFalpha-induced ICAM-1 expression, p65 nuclear translocation, NFkappaB and DNA binding activity, and THP-1 cell adhesion.	GW 6471	25-31	intercellular adhesion molecule 1	Homo sapiens	90-96
31499122-9	2019	The PPARalpha antagonist GW6471 reversed the inhibitory effect of DHA on TNFalpha-induced ICAM-1 expression, p65 nuclear translocation, NFkappaB and DNA binding activity, and THP-1 cell adhesion.	GW 6471	25-31	RELA proto-oncogene, NF-kB subunit	Homo sapiens	109-112
31499122-9	2019	The PPARalpha antagonist GW6471 reversed the inhibitory effect of DHA on TNFalpha-induced ICAM-1 expression, p65 nuclear translocation, NFkappaB and DNA binding activity, and THP-1 cell adhesion.	GW 6471	25-31	nuclear factor kappa B subunit 1	Homo sapiens	136-144
31775380-5	2019	Moreover, WY-14643 plus GW6471, a PPARalpha antagonist, significantly inhibited the WY-14643-mediated increase in CYP1B1 expression.	GW 6471	24-30	peroxisome proliferator activated receptor alpha	Homo sapiens	34-43
31775380-5	2019	Moreover, WY-14643 plus GW6471, a PPARalpha antagonist, significantly inhibited the WY-14643-mediated increase in CYP1B1 expression.	GW 6471	24-30	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	114-120
31141879-15	2019	Vitamin D3, rosiglitazone, novel RXR compound (RXRc) and PPARa compound (GW6471) have the most profound effects.	GW 6471	73-79	peroxisome proliferator activated receptor alpha	Homo sapiens	57-62
31274012-6	2019	When PPARalpha activation was blocked by GW6471, OA-induced Plin5 expression and lipid droplets formation were effectively ablated.	GW 6471	41-47	peroxisome proliferator activated receptor alpha	Homo sapiens	5-14
31274012-6	2019	When PPARalpha activation was blocked by GW6471, OA-induced Plin5 expression and lipid droplets formation were effectively ablated.	GW 6471	41-47	perilipin 5	Homo sapiens	60-65
31028997-9	2019	Most importantly, the protective effects were abrogated by GW6471 (a PPARalpha inhibitor) and ameliorated by Wy14643 (a PPARalpha agonist).	GW 6471	59-65	peroxisome proliferator activated receptor alpha	Rattus norvegicus	69-78
31241159-5	2019	TP-induced liver injury could be alleviated by treatment of mice with the PPARalpha agonist fenofibrate, while the PPARalpha antagonist GW6471 increased hepatotoxicity.	GW 6471	136-142	peroxisome proliferator activated receptor alpha	Mus musculus	115-124
31033195-9	2019	More importantly, the PPARalpha-specific inhibitor GW6471 partially abolished the beneficial effects of bromide on mouse PHs.	GW 6471	51-57	peroxisome proliferator activated receptor alpha	Mus musculus	22-31
29859326-4	2018	DHA alone or along with the PPARalpha antagonist GW6471 were administered to mice by intracerebroventricular (i.c.v.)	GW 6471	49-55	peroxisome proliferator activated receptor alpha	Mus musculus	28-37
29567093-7	2019	Our respective in vitro and in vivo observations that OlGly activated peroxisome proliferator-activated receptor alpha (PPAR-alpha) and the PPAR-alpha antagonist GW6471 prevented the OlGly-induced reduction of nicotine CPP in mice suggests that this lipid acts as a functional PPAR-alpha agonist to attenuate nicotine reward.	GW 6471	162-168	peroxisome proliferator activated receptor alpha	Mus musculus	140-150
29567093-7	2019	Our respective in vitro and in vivo observations that OlGly activated peroxisome proliferator-activated receptor alpha (PPAR-alpha) and the PPAR-alpha antagonist GW6471 prevented the OlGly-induced reduction of nicotine CPP in mice suggests that this lipid acts as a functional PPAR-alpha agonist to attenuate nicotine reward.	GW 6471	162-168	peroxisome proliferator activated receptor alpha	Mus musculus	140-150
30884817-6	2019	The cyanidin-induced elevation of Mg2+ transport carriers was blocked by GW6471, a peroxisome proliferator-activated receptor alpha (PPARalpha) inhibitor, but not by PPARgamma, PPARdelta, and protein kinase A inhibitors.	GW 6471	73-79	peroxisome proliferator activated receptor alpha	Mus musculus	83-131
30884817-6	2019	The cyanidin-induced elevation of Mg2+ transport carriers was blocked by GW6471, a peroxisome proliferator-activated receptor alpha (PPARalpha) inhibitor, but not by PPARgamma, PPARdelta, and protein kinase A inhibitors.	GW 6471	73-79	peroxisome proliferator activated receptor alpha	Mus musculus	133-142
30884817-9	2019	The nuclear localization of PPARalpha and reporter activities of Mg2+ transport carriers were increased by cyanidin, which were inhibited by GW6471.	GW 6471	141-147	peroxisome proliferator activated receptor alpha	Mus musculus	28-37
30611723-9	2019	These effects on gene expression were lost when the cells were co-treated with the PPARalpha antagonist, GW6471.	GW 6471	105-111	peroxisome proliferator activated receptor alpha	Homo sapiens	83-92
30521668-11	2018	GW6471 also reduced the density of ME1- and apoA-II-stained cells in unoccluded eyes whereas bezafibrate increased apoA-II-positive cell numbers in form-deprived eyes.	GW 6471	0-6	NADP-dependent malic enzyme	Cavia porcellus	35-38
30521668-12	2018	Conclusions: As GW7647 and GW6471 had opposing effects on myopia development, PPARalpha signaling modulation may be involved in this condition in guinea pigs.	GW 6471	27-33	peroxisome proliferator-activated receptor alpha	Cavia porcellus	78-87
30358936-7	2018	Inhibiting the function of Pparalpha by using either the PPARalpha/Pparalpha antagonist GW6471 or pparaa or pparab truncated constructs produced identical phenotypes, which were sufficient to reduce the proliferation of neuronal and glial precursor cells without affecting the formation of neural progenitors.	GW 6471	88-94	peroxisome proliferator-activated receptor alpha b	Danio rerio	27-36
30201376-6	2018	PPARalpha specific antagonist GW6471 attenuate K-877 induced ABCA1 expression in INS-1 cells.	GW 6471	30-36	peroxisome proliferator activated receptor alpha	Rattus norvegicus	0-9
30201376-6	2018	PPARalpha specific antagonist GW6471 attenuate K-877 induced ABCA1 expression in INS-1 cells.	GW 6471	30-36	ATP binding cassette subfamily A member 1	Rattus norvegicus	61-66
30660821-9	2019	PPARalpha antagonist GW6471 abolished the effect of OEA on glial activation.	GW 6471	21-27	peroxisome proliferator activated receptor alpha	Mus musculus	0-9
29725299-4	2018	Mice subjected to HI were treated with the PPAR-alpha antagonist GW6471 (GW) (1 mg/kg) followed 15 min later by SUL (3 and 10 mg/kg).	GW 6471	65-71	peroxisome proliferator activated receptor alpha	Mus musculus	43-53
29935534-9	2018	The results indicated that NF-kappaB-mediated transcriptional activity was significantly decreased by 3RS, 7R, 11R-PA and that GW6471, an antagonist of peroxisome proliferator activated receptor alpha (PPARalpha), abrogated the inhibitory effect of 3RS, 7R, 11R-PA on NF-kappaB activity.	GW 6471	127-133	peroxisome proliferator activated receptor alpha	Homo sapiens	152-200
29935534-9	2018	The results indicated that NF-kappaB-mediated transcriptional activity was significantly decreased by 3RS, 7R, 11R-PA and that GW6471, an antagonist of peroxisome proliferator activated receptor alpha (PPARalpha), abrogated the inhibitory effect of 3RS, 7R, 11R-PA on NF-kappaB activity.	GW 6471	127-133	peroxisome proliferator activated receptor alpha	Homo sapiens	202-211
30082018-10	2018	The expression of PPARalpha and its downstream gene Cyp4a1 in GW6471 + PFOA group was higher than that in PPARalpha inhibitor group( P < 0.	GW 6471	62-68	peroxisome proliferator activated receptor alpha	Rattus norvegicus	18-27
30082018-10	2018	The expression of PPARalpha and its downstream gene Cyp4a1 in GW6471 + PFOA group was higher than that in PPARalpha inhibitor group( P < 0.	GW 6471	62-68	cytochrome P450, family 4, subfamily a, polypeptide 1	Rattus norvegicus	52-58
30082018-15	2018	The protein expression of PPARalpha in GW6471 + PFOA group was up-regulated compared with the inhibitor group, there was no difference compared with the blank control group.	GW 6471	39-45	peroxisome proliferator activated receptor alpha	Rattus norvegicus	26-35
29618584-9	2018	The MTX plasma concentration change induced by LEF was reversed by the PPARalpha-specific antagonist GW6471.	GW 6471	101-107	peroxisome proliferator activated receptor alpha	Mus musculus	71-80
29725299-4	2018	Mice subjected to HI were treated with the PPAR-alpha antagonist GW6471 (GW) (1 mg/kg) followed 15 min later by SUL (3 and 10 mg/kg).	GW 6471	65-67	peroxisome proliferator activated receptor alpha	Mus musculus	43-53
29059162-7	2018	Small interfering RNA-mediated PPARalpha silencing and PPARalpha blockade by the antagonist GW6471 abolish the effect of clofibrate on radiosensitization.	GW 6471	92-98	peroxisome proliferator activated receptor alpha	Homo sapiens	55-64
28918014-7	2017	Furthermore, the PPARalpha agonist GW6471 could partially restore the effect of A20 on VSMCs.	GW 6471	35-41	peroxisome proliferator activated receptor alpha	Rattus norvegicus	17-26
28954820-11	2017	PEA effects were blocked by the PPARalpha antagonist GW6471.	GW 6471	53-59	peroxisome proliferator activated receptor alpha	Homo sapiens	32-41
29190977-6	2017	GW7647 inhibition of proton-gated currents can be blocked by GW6471, a selective PPAR-alpha antagonist.	GW 6471	61-67	peroxisome proliferator activated receptor alpha	Rattus norvegicus	81-91
28716724-7	2017	Another PPARalpha activator, bezafibrate and PPARalpha inhibitor, GW 6471, did not affect the Kv current and also did not change the inhibitory effect of fenofibrate on the Kv current.	GW 6471	66-73	peroxisome proliferator-activated receptor alpha	Oryctolagus cuniculus	8-17
28716724-7	2017	Another PPARalpha activator, bezafibrate and PPARalpha inhibitor, GW 6471, did not affect the Kv current and also did not change the inhibitory effect of fenofibrate on the Kv current.	GW 6471	66-73	peroxisome proliferator-activated receptor alpha	Oryctolagus cuniculus	45-54
27193034-5	2017	These effects were blocked by the PPAR- alpha antagonist, GW6471.	GW 6471	58-64	peroxisome proliferator activated receptor alpha	Rattus norvegicus	34-45
28606623-6	2017	Interestingly, the selective PPAR-alpha antagonist GW6471 blocked the antinociceptive effects of PNU282987, but did not alter the antinociceptive responses evoked by the alpha7 nAChR PAM PNU120596, ago-PAM GAT107, and silent agonist NS6740.	GW 6471	51-57	peroxisome proliferator activated receptor alpha	Mus musculus	29-39
28587983-8	2017	Co-incubation with 6-(2-proparglyloxyphenyl) hexanoic acid (PPOH) and PPARalpha inhibitor GW6471 before drug treatment abolished the endothelium protective effects of OP-D. Taken together, these data suggest that OP-D has the endothelial protective effect through activation of CYP2J and increasing EETs, and PPARalpha involves in this process.	GW 6471	90-96	peroxisome proliferator activated receptor alpha	Homo sapiens	70-79
28587983-8	2017	Co-incubation with 6-(2-proparglyloxyphenyl) hexanoic acid (PPOH) and PPARalpha inhibitor GW6471 before drug treatment abolished the endothelium protective effects of OP-D. Taken together, these data suggest that OP-D has the endothelial protective effect through activation of CYP2J and increasing EETs, and PPARalpha involves in this process.	GW 6471	90-96	peroxisome proliferator activated receptor alpha	Homo sapiens	309-318
29312541-7	2017	Treatment with the PPARalpha antagonist GW6471 resulted in decreased cell proliferation and neurospheres formation.	GW 6471	40-46	peroxisome proliferator activated receptor alpha	Homo sapiens	19-28
28594934-9	2017	The specific PPARalpha agonist WY14643 had no effect on HNPGL cell viability, whereas the specific PPARalpha antagonist GW6471 reduced HNPGL cell viability and growth by inducing cell cycle arrest and caspase-dependent apoptosis.	GW 6471	120-126	peroxisome proliferator activated receptor alpha	Homo sapiens	99-108
28594934-10	2017	GW6471 treatment was associated with a marked decrease of CDK4, cyclin D3 and cyclin B1 protein expression, along with an increased expression of p21 in HNPGL cells.	GW 6471	0-6	cyclin dependent kinase 4	Homo sapiens	58-62
28594934-10	2017	GW6471 treatment was associated with a marked decrease of CDK4, cyclin D3 and cyclin B1 protein expression, along with an increased expression of p21 in HNPGL cells.	GW 6471	0-6	cyclin D3	Homo sapiens	64-73
28594934-10	2017	GW6471 treatment was associated with a marked decrease of CDK4, cyclin D3 and cyclin B1 protein expression, along with an increased expression of p21 in HNPGL cells.	GW 6471	0-6	cyclin B1	Homo sapiens	78-87
28594934-10	2017	GW6471 treatment was associated with a marked decrease of CDK4, cyclin D3 and cyclin B1 protein expression, along with an increased expression of p21 in HNPGL cells.	GW 6471	0-6	H3 histone pseudogene 16	Homo sapiens	146-149
28594934-12	2017	Notably, the effects of GW6471 on HNPGL cells were associated with the inhibition of the PI3K/GSK3beta/beta-catenin signaling pathway.	GW 6471	24-30	glycogen synthase kinase 3 beta	Homo sapiens	94-102
28594934-12	2017	Notably, the effects of GW6471 on HNPGL cells were associated with the inhibition of the PI3K/GSK3beta/beta-catenin signaling pathway.	GW 6471	24-30	catenin beta 1	Homo sapiens	103-115
28594934-13	2017	In conclusion, the PPARalpha antagonist GW6471 reduces HNPGL cell viability, interfering with cell cycle and inducing apoptosis.	GW 6471	40-46	peroxisome proliferator activated receptor alpha	Homo sapiens	19-28
28279662-8	2017	Our results demonstrate the PPARalpha antagonist GW6471 blocks actions of the alpha7 nAChR agonist PNU282987 on nicotine reward in an unbiased CPP test in male ICR adult mice.	GW 6471	49-55	peroxisome proliferator activated receptor alpha	Mus musculus	28-37
28279662-8	2017	Our results demonstrate the PPARalpha antagonist GW6471 blocks actions of the alpha7 nAChR agonist PNU282987 on nicotine reward in an unbiased CPP test in male ICR adult mice.	GW 6471	49-55	cholinergic receptor, nicotinic, alpha polypeptide 7	Mus musculus	78-90
28323206-6	2017	This reduction was prevented by the addition of the PPARalpha antagonist, GW6471.	GW 6471	74-80	peroxisome proliferator activated receptor alpha	Homo sapiens	52-61
26168851-9	2016	The reactive oxygen species (ROS) content in rat hepatocytes assayed by flow cytometry significantly increased in the PPARalpha knockdown groups, consistent with the PPARalpha antagonist GW6471- and agonist WY14643-treated groups.	GW 6471	187-193	peroxisome proliferator activated receptor alpha	Rattus norvegicus	118-127
27608657-8	2016	The PPAR-alpha antagonist receptor antagonist GW6471 [N-((2S)-2-(((1Z)-1-methyl-3-oxo-3-(4-(trifluoromethyl)phenyl)prop-1-enyl)amino)-3-(4-(2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy)phenyl)propyl)propanamide] completely blocked the antinociceptive effects of PEA.	GW 6471	46-52	peroxisome proliferator activated receptor alpha	Mus musculus	4-14
27422264-6	2016	The usage of both PPAR-alpha inhibitor GW6471 and BDNF system inhibitor K252a fully prevented the memory-enhancing effects of WY14643.	GW 6471	39-45	peroxisome proliferator activated receptor alpha	Mus musculus	18-28
27779188-8	2016	More importantly, we found that the cell cycle arrest at G0/G1 phase and the alterations of CDK4/6 and Cyclin D1 triggered by simvastatin could be recovered by PPARgamma-antagonist (GW9662), whereas the treatment of PPARalpha-antagonist (GW6471) shown no significant effects on the BCa cells.	GW 6471	238-244	cyclin dependent kinase 4	Homo sapiens	92-98
27779188-8	2016	More importantly, we found that the cell cycle arrest at G0/G1 phase and the alterations of CDK4/6 and Cyclin D1 triggered by simvastatin could be recovered by PPARgamma-antagonist (GW9662), whereas the treatment of PPARalpha-antagonist (GW6471) shown no significant effects on the BCa cells.	GW 6471	238-244	peroxisome proliferator activated receptor gamma	Homo sapiens	160-169
27845265-11	2017	These effects of GGH(4) were similar to those of the PPARalpha activator fenofibrate, whereas the PPARalpha antagonist GW6471 reversed the inhibitory effects of GGH(4) on lipid accumulation in HepG2 cells.	GW 6471	119-125	peroxisome proliferator activated receptor alpha	Homo sapiens	98-107
26082188-10	2016	Pretreatment of animals with a selective PPAR-alpha antagonist, GW6471, significantly improved doxorubicin-induced atrial dysfunction (P < 0.001).	GW 6471	64-70	peroxisome proliferator activated receptor alpha	Mus musculus	41-51
26082188-12	2016	Also, GW6471 and WIN significantly reduced cardiac MDA and TNF-alpha levels compared with animals receiving doxorubicin (P < 0.001).	GW 6471	6-12	tumor necrosis factor	Mus musculus	59-68
26597893-7	2016	BML-111 stimulated the renal expressions of pPPARalpha and HO-1, and cellular messenger RNA (mRNA) and protein expressions of pPPARalpha and HO-1 which were both blocked by GW6471, a selective PPARalpha antagonist, and ZnPP-IX, a specific inhibitor of HO-1 pretreatment.	GW 6471	173-179	heme oxygenase 1	Rattus norvegicus	59-63
26597893-7	2016	BML-111 stimulated the renal expressions of pPPARalpha and HO-1, and cellular messenger RNA (mRNA) and protein expressions of pPPARalpha and HO-1 which were both blocked by GW6471, a selective PPARalpha antagonist, and ZnPP-IX, a specific inhibitor of HO-1 pretreatment.	GW 6471	173-179	heme oxygenase 1	Rattus norvegicus	141-145
26597893-7	2016	BML-111 stimulated the renal expressions of pPPARalpha and HO-1, and cellular messenger RNA (mRNA) and protein expressions of pPPARalpha and HO-1 which were both blocked by GW6471, a selective PPARalpha antagonist, and ZnPP-IX, a specific inhibitor of HO-1 pretreatment.	GW 6471	173-179	peroxisome proliferator activated receptor alpha	Rattus norvegicus	45-54
26597893-7	2016	BML-111 stimulated the renal expressions of pPPARalpha and HO-1, and cellular messenger RNA (mRNA) and protein expressions of pPPARalpha and HO-1 which were both blocked by GW6471, a selective PPARalpha antagonist, and ZnPP-IX, a specific inhibitor of HO-1 pretreatment.	GW 6471	173-179	heme oxygenase 1	Rattus norvegicus	141-145
26597893-9	2016	The binding activity of PPARalpha to PPRE in nuclear extracts of NRK-52E cells was enhanced by treatment of the cells with BML-111, and was suppressed by GW6471 and SB203580.	GW 6471	154-160	peroxisome proliferator activated receptor alpha	Rattus norvegicus	24-33
27356604-7	2016	ACh alone and AACOCF3, an analogue of arachidonic acid (AA), induced the NOS1 phosphorylation via PI3K/Akt to produce NO, which was inhibited by GW6471.	GW 6471	145-151	nitric oxide synthase, brain	Cavia porcellus	73-77
25863588-9	2015	The effect of MINCH was blocked by the specific peroxisome proliferator-activated receptor (PPAR)-alpha antagonist, GW6471.	GW 6471	116-122	peroxisome proliferator activated receptor alpha	Rattus norvegicus	48-103
26226216-10	2015	Moreover, the effects of fenofibrate on cell apoptosis and SIRT1 expression in VAFs were reversed by PPARalpha antagonist GW6471.	GW 6471	122-128	sirtuin 1	Mus musculus	59-64
26226216-10	2015	Moreover, the effects of fenofibrate on cell apoptosis and SIRT1 expression in VAFs were reversed by PPARalpha antagonist GW6471.	GW 6471	122-128	peroxisome proliferator activated receptor alpha	Mus musculus	101-110
26068433-10	2015	However, the PPARalpha antagonist GW6471 reversed the inhibitory effects of GGH(4) on adipogenesis.	GW 6471	34-40	peroxisome proliferator activated receptor alpha	Rattus norvegicus	13-22
25810260-3	2015	We previously identified peroxisome proliferator-activating receptor-alpha (PPARalpha) as a potential therapeutic target for this disease and showed that a specific PPARalpha antagonist, GW6471, induced apoptosis and cell cycle arrest at G0/G1 in RCC cell lines associated with attenuation of cell cycle regulatory proteins.	GW 6471	187-193	peroxisome proliferator activated receptor alpha	Homo sapiens	76-85
25810260-5	2015	The specific PPARalpha inhibitor GW6471, as well as a siRNA specific to PPARalpha, attenuates the enhanced fatty acid oxidation and oxidative phosphorylation associated with glycolysis inhibition, and PPARalpha antagonism also blocks the enhanced glycolysis that has been observed in RCC cells; this effect did not occur in normal human kidney epithelial cells.	GW 6471	33-39	peroxisome proliferator activated receptor alpha	Homo sapiens	13-22
25810260-3	2015	We previously identified peroxisome proliferator-activating receptor-alpha (PPARalpha) as a potential therapeutic target for this disease and showed that a specific PPARalpha antagonist, GW6471, induced apoptosis and cell cycle arrest at G0/G1 in RCC cell lines associated with attenuation of cell cycle regulatory proteins.	GW 6471	187-193	peroxisome proliferator activated receptor alpha	Homo sapiens	165-174
25810260-7	2015	Furthermore, we show that treatment with GW6471 results in RCC tumor growth attenuation in a xenograft mouse model, with minimal obvious toxicity, a finding associated with the expected on-target effects on c-Myc.	GW 6471	41-47	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	207-212
25636810-7	2015	PPARalpha inhibitor GW6471 and PPARalpha activator Fenofibrate treatments abrogated the effects induced by IGF-1 and PE in cardiomyocytes respectively, as well as ERK1/2 activator EGF and ERK1/2 inhibitor PD98059.	GW 6471	20-26	mitogen activated protein kinase 3	Rattus norvegicus	188-194
25056757-5	2015	Addition of the PPAR-alpha antagonist GW6471 to PFOS-dosed cells stimulated with PHA/PMA resulted in decreases in IL-2 production starting at 50 microg PFOS ml(-1), which suggests PFOS affected T-cell IL-2 production via PPAR-alpha-independent mechanisms.	GW 6471	38-44	peroxisome proliferator activated receptor alpha	Homo sapiens	16-26
25056757-5	2015	Addition of the PPAR-alpha antagonist GW6471 to PFOS-dosed cells stimulated with PHA/PMA resulted in decreases in IL-2 production starting at 50 microg PFOS ml(-1), which suggests PFOS affected T-cell IL-2 production via PPAR-alpha-independent mechanisms.	GW 6471	38-44	interleukin 2	Homo sapiens	114-118
25056757-5	2015	Addition of the PPAR-alpha antagonist GW6471 to PFOS-dosed cells stimulated with PHA/PMA resulted in decreases in IL-2 production starting at 50 microg PFOS ml(-1), which suggests PFOS affected T-cell IL-2 production via PPAR-alpha-independent mechanisms.	GW 6471	38-44	interleukin 2	Homo sapiens	201-205
25056757-5	2015	Addition of the PPAR-alpha antagonist GW6471 to PFOS-dosed cells stimulated with PHA/PMA resulted in decreases in IL-2 production starting at 50 microg PFOS ml(-1), which suggests PFOS affected T-cell IL-2 production via PPAR-alpha-independent mechanisms.	GW 6471	38-44	peroxisome proliferator activated receptor alpha	Homo sapiens	221-231
25463999-9	2015	The CB1 antagonist rimonabant and the PPARalpha antagonist GW6471 counteracted the beneficial effect of PEA on gross damage.	GW 6471	59-65	peroxisome proliferator activated receptor alpha	Rattus norvegicus	38-47
25636810-7	2015	PPARalpha inhibitor GW6471 and PPARalpha activator Fenofibrate treatments abrogated the effects induced by IGF-1 and PE in cardiomyocytes respectively, as well as ERK1/2 activator EGF and ERK1/2 inhibitor PD98059.	GW 6471	20-26	peroxisome proliferator activated receptor alpha	Rattus norvegicus	0-9
25636810-7	2015	PPARalpha inhibitor GW6471 and PPARalpha activator Fenofibrate treatments abrogated the effects induced by IGF-1 and PE in cardiomyocytes respectively, as well as ERK1/2 activator EGF and ERK1/2 inhibitor PD98059.	GW 6471	20-26	insulin-like growth factor 1	Rattus norvegicus	107-112
25881202-9	2015	In experiments designed to clarify if the effects of the two agents are PPARalpha-dependent, induction of mRNA and secretion beta-defensin 1 and inhibition of chemokine release were clearly reduced with GW6471, a PPARalpha blocker.	GW 6471	203-209	peroxisome proliferator activated receptor alpha	Homo sapiens	72-81
25881202-9	2015	In experiments designed to clarify if the effects of the two agents are PPARalpha-dependent, induction of mRNA and secretion beta-defensin 1 and inhibition of chemokine release were clearly reduced with GW6471, a PPARalpha blocker.	GW 6471	203-209	defensin beta 1	Homo sapiens	125-140
25496486-7	2015	Treatment of cells with AA and GW6471 or bisphenol A diglycidyl ether (BADGE), PPARalpha or PPARgamma antagonists, respectively, reversed the effect on UVB-induced MMP-1 expression and inflammatory signalling pathway activation.	GW 6471	31-37	matrix metallopeptidase 1	Homo sapiens	164-169
25832022-9	2015	The PPAR-alpha antagonist, GW6471, inhibited the induction of the PPAR-alpha downstream genes by OLHA and N-oleoylethanolamide (OEA).	GW 6471	27-33	peroxisome proliferator activated receptor alpha	Rattus norvegicus	4-14
25832022-9	2015	The PPAR-alpha antagonist, GW6471, inhibited the induction of the PPAR-alpha downstream genes by OLHA and N-oleoylethanolamide (OEA).	GW 6471	27-33	peroxisome proliferator activated receptor alpha	Rattus norvegicus	66-76
25291543-5	2014	Results showed that, PPARalpha was activated in DBP-exposed Sertoli cells, GW6471 inhibited the activity of PPARalpha, phosphorylation level of vimentin and concentration of soluble vimentin was higher in DBP-treated Sertoli cells than GW6471+DBP-treated cells.	GW 6471	75-81	peroxisome proliferator activated receptor alpha	Rattus norvegicus	108-117
26819576-8	2015	WY14643 (an agonist of PPARalpha) pretreatment stimulated, while GW6471 (an antagonist of PPARalpha) inhibited, the activity of Smad2/3; SB431542 pretreatment also inhibited the activity of PPARalpha, but it did not rescue the DBP-induced collapse in vimentin.	GW 6471	65-71	peroxisome proliferator activated receptor alpha	Homo sapiens	90-99
26819576-8	2015	WY14643 (an agonist of PPARalpha) pretreatment stimulated, while GW6471 (an antagonist of PPARalpha) inhibited, the activity of Smad2/3; SB431542 pretreatment also inhibited the activity of PPARalpha, but it did not rescue the DBP-induced collapse in vimentin.	GW 6471	65-71	SMAD family member 2	Homo sapiens	128-135
26819576-8	2015	WY14643 (an agonist of PPARalpha) pretreatment stimulated, while GW6471 (an antagonist of PPARalpha) inhibited, the activity of Smad2/3; SB431542 pretreatment also inhibited the activity of PPARalpha, but it did not rescue the DBP-induced collapse in vimentin.	GW 6471	65-71	peroxisome proliferator activated receptor alpha	Homo sapiens	90-99
25801844-11	2015	Finally, the peroxisome proliferator-activated receptor alpha inhibitor GW6471, added to Abeta-treated C6 cells blocked all PEA effects in this model, suggesting that PEA acts through a proliferator-activated receptor alpha-dependent mechanism on astroglial cells.	GW 6471	72-78	peroxisome proliferator activated receptor alpha	Homo sapiens	13-61
25342048-2	2014	GW7647 [a peroxisome proliferation activation receptor alpha (PPARalpha) agonist] enhanced the ACh-stimulated initial phase, and GW6471 (a PPARalpha antagonist) abolished the GW7647-induced enhancement.	GW 6471	129-135	peroxisome proliferator-activated receptor alpha	Cavia porcellus	139-148
25291543-5	2014	Results showed that, PPARalpha was activated in DBP-exposed Sertoli cells, GW6471 inhibited the activity of PPARalpha, phosphorylation level of vimentin and concentration of soluble vimentin was higher in DBP-treated Sertoli cells than GW6471+DBP-treated cells.	GW 6471	75-81	vimentin	Rattus norvegicus	144-152
25291543-5	2014	Results showed that, PPARalpha was activated in DBP-exposed Sertoli cells, GW6471 inhibited the activity of PPARalpha, phosphorylation level of vimentin and concentration of soluble vimentin was higher in DBP-treated Sertoli cells than GW6471+DBP-treated cells.	GW 6471	75-81	vimentin	Rattus norvegicus	182-190
25019995-6	2014	Treatment of cells with SHQA and GW6471 (PPARalpha antagonist) not bisphenol A diglycidyl ether (PPARgamma antagonists), reversed the effect on TNFalpha-induced inflammatory signaling pathway activation.	GW 6471	33-39	peroxisome proliferator activated receptor alpha	Homo sapiens	41-50
25210802-4	2014	Moreover, to investigate the molecular mechanisms responsible for the effects induced by PEA, we co-administered PEA with the GW6471, an antagonist of peroxisome proliferator-activated receptor-alpha (PPAR-alpha).	GW 6471	126-132	peroxisome proliferator activated receptor alpha	Rattus norvegicus	151-199
25210802-4	2014	Moreover, to investigate the molecular mechanisms responsible for the effects induced by PEA, we co-administered PEA with the GW6471, an antagonist of peroxisome proliferator-activated receptor-alpha (PPAR-alpha).	GW 6471	126-132	peroxisome proliferator activated receptor alpha	Rattus norvegicus	201-211
25014183-4	2014	The role of PPARalpha in these pharmacological responses was confirmed by the ability of the PPARalpha antagonist GW6471 (10 muM) to block CLO-, WY14643- and GW7647-induced TRPV1 activation, and by the observation that modulation of PPARalpha levels via siRNA-mediated suppression or PPARalpha over-expression affected TRPV1 channel activation by PPARalpha agonists accordingly.	GW 6471	114-120	peroxisome proliferator-activated receptor alpha	Cricetulus griseus	12-21
25014183-4	2014	The role of PPARalpha in these pharmacological responses was confirmed by the ability of the PPARalpha antagonist GW6471 (10 muM) to block CLO-, WY14643- and GW7647-induced TRPV1 activation, and by the observation that modulation of PPARalpha levels via siRNA-mediated suppression or PPARalpha over-expression affected TRPV1 channel activation by PPARalpha agonists accordingly.	GW 6471	114-120	peroxisome proliferator-activated receptor alpha	Cricetulus griseus	93-102
25014183-4	2014	The role of PPARalpha in these pharmacological responses was confirmed by the ability of the PPARalpha antagonist GW6471 (10 muM) to block CLO-, WY14643- and GW7647-induced TRPV1 activation, and by the observation that modulation of PPARalpha levels via siRNA-mediated suppression or PPARalpha over-expression affected TRPV1 channel activation by PPARalpha agonists accordingly.	GW 6471	114-120	LOW QUALITY PROTEIN: transient receptor potential cation channel subfamily V member 1	Cricetulus griseus	173-178
25014183-4	2014	The role of PPARalpha in these pharmacological responses was confirmed by the ability of the PPARalpha antagonist GW6471 (10 muM) to block CLO-, WY14643- and GW7647-induced TRPV1 activation, and by the observation that modulation of PPARalpha levels via siRNA-mediated suppression or PPARalpha over-expression affected TRPV1 channel activation by PPARalpha agonists accordingly.	GW 6471	114-120	peroxisome proliferator-activated receptor alpha	Cricetulus griseus	93-102
25014183-4	2014	The role of PPARalpha in these pharmacological responses was confirmed by the ability of the PPARalpha antagonist GW6471 (10 muM) to block CLO-, WY14643- and GW7647-induced TRPV1 activation, and by the observation that modulation of PPARalpha levels via siRNA-mediated suppression or PPARalpha over-expression affected TRPV1 channel activation by PPARalpha agonists accordingly.	GW 6471	114-120	peroxisome proliferator-activated receptor alpha	Cricetulus griseus	93-102
25014183-4	2014	The role of PPARalpha in these pharmacological responses was confirmed by the ability of the PPARalpha antagonist GW6471 (10 muM) to block CLO-, WY14643- and GW7647-induced TRPV1 activation, and by the observation that modulation of PPARalpha levels via siRNA-mediated suppression or PPARalpha over-expression affected TRPV1 channel activation by PPARalpha agonists accordingly.	GW 6471	114-120	LOW QUALITY PROTEIN: transient receptor potential cation channel subfamily V member 1	Cricetulus griseus	319-324
25014183-4	2014	The role of PPARalpha in these pharmacological responses was confirmed by the ability of the PPARalpha antagonist GW6471 (10 muM) to block CLO-, WY14643- and GW7647-induced TRPV1 activation, and by the observation that modulation of PPARalpha levels via siRNA-mediated suppression or PPARalpha over-expression affected TRPV1 channel activation by PPARalpha agonists accordingly.	GW 6471	114-120	peroxisome proliferator-activated receptor alpha	Cricetulus griseus	93-102
25170294-12	2014	GW6471 and T0070907 inhibit osteoblastic differentiation of the periosteal-derived cells by decreasing ALP expression and mineralization in the periosteal-derived cells.	GW 6471	0-6	alkaline phosphatase, placental	Homo sapiens	103-106
25019995-6	2014	Treatment of cells with SHQA and GW6471 (PPARalpha antagonist) not bisphenol A diglycidyl ether (PPARgamma antagonists), reversed the effect on TNFalpha-induced inflammatory signaling pathway activation.	GW 6471	33-39	tumor necrosis factor	Homo sapiens	144-152
24210485-4	2014	The results show that WY-14,643 increases mRNA and protein levels of OCTN2, whereas co-treatment of MDBK cells with WY-14,643 and the PPARalpha antagonist GW6471 blocks the WY-14,643-induced increase in mRNA and protein levels of OCTN2 in bovine cells.	GW 6471	155-161	peroxisome proliferator activated receptor alpha	Bos taurus	134-143
24169105-13	2014	These effects were abolished after blocking PPARalpha with the selective antagonist GW6471.	GW 6471	84-90	peroxisome proliferator activated receptor alpha	Rattus norvegicus	44-53
24493576-8	2014	Inhibition of PPARalpha with specific inhibitor GW6471 did not affect either proliferation or apoptosis suggesting that these are PPARalpha-independent effects.	GW 6471	48-54	peroxisome proliferator activated receptor alpha	Homo sapiens	14-23
24022598-5	2014	The results showed that fenofibrate upregulated SIRT1 expression and inhibited CD40 expression in TNF-alpha-stimulated endothelial cells, but these effects were reversed by peroxisome proliferator-activated receptor-alpha (PPARalpha) antagonist GW6471.	GW 6471	245-251	peroxisome proliferator activated receptor alpha	Homo sapiens	173-221
24022598-5	2014	The results showed that fenofibrate upregulated SIRT1 expression and inhibited CD40 expression in TNF-alpha-stimulated endothelial cells, but these effects were reversed by peroxisome proliferator-activated receptor-alpha (PPARalpha) antagonist GW6471.	GW 6471	245-251	peroxisome proliferator activated receptor alpha	Homo sapiens	223-232
23951092-6	2013	A specific PPARalpha antagonist, GW6471, induced both apoptosis and cell cycle arrest at G0/G1 in VHL(+) and VHL(-) RCC cell lines (786-O and Caki-1) associated with attenuation of the cell cycle regulatory proteins c-Myc, Cyclin D1, and CDK4; this data was confirmed as specific to PPARalpha antagonism by siRNA methods.	GW 6471	33-39	peroxisome proliferator activated receptor alpha	Homo sapiens	11-20
23951092-6	2013	A specific PPARalpha antagonist, GW6471, induced both apoptosis and cell cycle arrest at G0/G1 in VHL(+) and VHL(-) RCC cell lines (786-O and Caki-1) associated with attenuation of the cell cycle regulatory proteins c-Myc, Cyclin D1, and CDK4; this data was confirmed as specific to PPARalpha antagonism by siRNA methods.	GW 6471	33-39	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	216-221
23951092-6	2013	A specific PPARalpha antagonist, GW6471, induced both apoptosis and cell cycle arrest at G0/G1 in VHL(+) and VHL(-) RCC cell lines (786-O and Caki-1) associated with attenuation of the cell cycle regulatory proteins c-Myc, Cyclin D1, and CDK4; this data was confirmed as specific to PPARalpha antagonism by siRNA methods.	GW 6471	33-39	cyclin D1	Homo sapiens	223-232
23951092-6	2013	A specific PPARalpha antagonist, GW6471, induced both apoptosis and cell cycle arrest at G0/G1 in VHL(+) and VHL(-) RCC cell lines (786-O and Caki-1) associated with attenuation of the cell cycle regulatory proteins c-Myc, Cyclin D1, and CDK4; this data was confirmed as specific to PPARalpha antagonism by siRNA methods.	GW 6471	33-39	cyclin dependent kinase 4	Homo sapiens	238-242
23951092-6	2013	A specific PPARalpha antagonist, GW6471, induced both apoptosis and cell cycle arrest at G0/G1 in VHL(+) and VHL(-) RCC cell lines (786-O and Caki-1) associated with attenuation of the cell cycle regulatory proteins c-Myc, Cyclin D1, and CDK4; this data was confirmed as specific to PPARalpha antagonism by siRNA methods.	GW 6471	33-39	peroxisome proliferator activated receptor alpha	Homo sapiens	283-292
23053988-7	2012	Moreover, GW6471 prevented the IGF-I promoting effect of ALA.	GW 6471	10-16	insulin like growth factor 1	Homo sapiens	31-36
23083124-7	2013	The TRPV1 antagonists capsazepine (1 muM) and SB-366791 (1 muM), as well as the PPARalpha antagonist GW-6471 (10 muM), inhibited PEA-induced [Ca2+](i) increase; blockers of cannabinoid receptors were ineffective.	GW 6471	101-108	peroxisome proliferator-activated receptor alpha	Cricetulus griseus	80-89
23534555-9	2013	In contrast, pretreatment with the PPARalpha-antagonist GW-6471 prevented the up-regulation of LFABP mRNA induced by IL-6 in the late phase of LFABP kinetics.	GW 6471	56-63	peroxisome proliferator activated receptor alpha	Mus musculus	35-44
23534555-9	2013	In contrast, pretreatment with the PPARalpha-antagonist GW-6471 prevented the up-regulation of LFABP mRNA induced by IL-6 in the late phase of LFABP kinetics.	GW 6471	56-63	fatty acid binding protein 1, liver	Mus musculus	95-100
23534555-9	2013	In contrast, pretreatment with the PPARalpha-antagonist GW-6471 prevented the up-regulation of LFABP mRNA induced by IL-6 in the late phase of LFABP kinetics.	GW 6471	56-63	interleukin 6	Mus musculus	117-121
23534555-9	2013	In contrast, pretreatment with the PPARalpha-antagonist GW-6471 prevented the up-regulation of LFABP mRNA induced by IL-6 in the late phase of LFABP kinetics.	GW 6471	56-63	fatty acid binding protein 1, liver	Mus musculus	143-148
23603572-5	2013	We found that fenofibrate inhibited CD40 expression and up-regulated SIRT1 expression in tumor necrosis factor-alpha (TNF-alpha)-stimulated adipocytes, and these effects of fenofibrate were reversed by PPARalpha antagonist GW6471.	GW 6471	223-229	tumor necrosis factor	Homo sapiens	89-116
23603572-5	2013	We found that fenofibrate inhibited CD40 expression and up-regulated SIRT1 expression in tumor necrosis factor-alpha (TNF-alpha)-stimulated adipocytes, and these effects of fenofibrate were reversed by PPARalpha antagonist GW6471.	GW 6471	223-229	tumor necrosis factor	Homo sapiens	118-127
23603572-5	2013	We found that fenofibrate inhibited CD40 expression and up-regulated SIRT1 expression in tumor necrosis factor-alpha (TNF-alpha)-stimulated adipocytes, and these effects of fenofibrate were reversed by PPARalpha antagonist GW6471.	GW 6471	223-229	peroxisome proliferator activated receptor alpha	Homo sapiens	202-211
23218523-7	2013	The antinociceptive effects of ARN077 were prevented by the selective PPAR-alpha antagonist GW6471 and did not occur in PPAR-alpha-deficient mice.	GW 6471	92-98	peroxisome proliferator activated receptor alpha	Mus musculus	70-80
22879419-7	2012	The protective effects of MG-132 pretreatment were partially reversed by the PPARalpha antagonist GW6471 but not by the PPARgamma antagonist GW9662; in contrast, neither agent reduced the protective effects of LA.	GW 6471	98-104	peroxisome proliferator activated receptor alpha	Homo sapiens	77-86
22972997-5	2012	The PPARalpha antagonist GW6471 blocked the effect of each.	GW 6471	25-31	peroxisome proliferator activated receptor alpha	Mus musculus	4-13
22266374-3	2012	We demonstrate that PPARalpha-selective ligands (i.e., clofibrate, GW7647) significantly induce BCRP mRNA and protein expression in a time- and concentration-dependent manner, whereas pharmacological inhibitors (i.e., MK886, GW6471) prevent this induction.	GW 6471	225-231	peroxisome proliferator activated receptor alpha	Homo sapiens	20-29
22654113-5	2012	Using the PPARalpha antagonist GW6471, we demonstrate that R(+)WIN55,212-2 acts via PPARalpha to activate JNK, activator protein-1, and positive regulatory domain IV to transcriptionally regulate the IFN-beta promoter.	GW 6471	31-37	peroxisome proliferator activated receptor alpha	Mus musculus	10-19
22654113-5	2012	Using the PPARalpha antagonist GW6471, we demonstrate that R(+)WIN55,212-2 acts via PPARalpha to activate JNK, activator protein-1, and positive regulatory domain IV to transcriptionally regulate the IFN-beta promoter.	GW 6471	31-37	peroxisome proliferator activated receptor alpha	Mus musculus	84-93
22654113-5	2012	Using the PPARalpha antagonist GW6471, we demonstrate that R(+)WIN55,212-2 acts via PPARalpha to activate JNK, activator protein-1, and positive regulatory domain IV to transcriptionally regulate the IFN-beta promoter.	GW 6471	31-37	mitogen-activated protein kinase 8	Mus musculus	106-109
22654113-5	2012	Using the PPARalpha antagonist GW6471, we demonstrate that R(+)WIN55,212-2 acts via PPARalpha to activate JNK, activator protein-1, and positive regulatory domain IV to transcriptionally regulate the IFN-beta promoter.	GW 6471	31-37	jun proto-oncogene	Mus musculus	111-130
22654113-5	2012	Using the PPARalpha antagonist GW6471, we demonstrate that R(+)WIN55,212-2 acts via PPARalpha to activate JNK, activator protein-1, and positive regulatory domain IV to transcriptionally regulate the IFN-beta promoter.	GW 6471	31-37	interferon beta 1, fibroblast	Mus musculus	200-208
22589443-6	2012	Pretreatment of anterior segments with 1 muM cannabinoid receptor 2 antagonist SR144528 and 1 muM PPARalpha antagonist GW6471, but not 1 muM cannabinoid receptor 1 antagonist SR141716A, produced a partial antagonism on the PEA-induced increase of outflow facility.	GW 6471	119-125	peroxisome proliferator activated receptor alpha	Homo sapiens	98-107
22589443-7	2012	Treatment of TM cells with PEA for 10 minutes activated phosphorylation of p42/44 MAPK, which was blocked by pretreatment with SR1444528 and GW6471, but not SR141716A.	GW 6471	141-147	cyclin dependent kinase 20	Homo sapiens	75-78
22429572-5	2012	The vasorelaxation to endocannabinoids was inhibited by PPARalpha antagonist GW6471 (1muM), but not the PPAR gamma (PPARgamma) antagonist GW9662 (1 muM).	GW 6471	77-83	peroxisome proliferator activated receptor alpha	Bos taurus	56-65
22232299-10	2012	In addition, oxLDL-induced NPC1 expression and cellular cholesterol efflux were reversed by PPARalpha siRNA or GW6471, an antagonist of PPARalpha.	GW 6471	111-117	NPC intracellular cholesterol transporter 1	Homo sapiens	27-31
22178921-4	2012	These effects were prevented by a selective PPAR-alpha antagonist, GW6471 and by a large-conductance Ca(2+)-activated K(+) channel inhibitor, charybdotoxin.	GW 6471	67-73	peroxisome proliferator activated receptor alpha	Rattus norvegicus	44-54
22232299-10	2012	In addition, oxLDL-induced NPC1 expression and cellular cholesterol efflux were reversed by PPARalpha siRNA or GW6471, an antagonist of PPARalpha.	GW 6471	111-117	peroxisome proliferator activated receptor alpha	Homo sapiens	136-145
22024046-7	2011	Adiponectin-induced HAS2 mRNA expression was blocked by GW6471, a PPARalpha antagonist, in a concentration-dependent manner.	GW 6471	56-62	adiponectin, C1Q and collagen domain containing	Homo sapiens	0-11
22208561-6	2011	However, administration of PPARalpha antagonist GW6471 for 2 weeks promoted the inflammatory response.	GW 6471	48-54	peroxisome proliferator activated receptor alpha	Mus musculus	27-36
22024046-7	2011	Adiponectin-induced HAS2 mRNA expression was blocked by GW6471, a PPARalpha antagonist, in a concentration-dependent manner.	GW 6471	56-62	hyaluronan synthase 2	Homo sapiens	20-24
22024046-7	2011	Adiponectin-induced HAS2 mRNA expression was blocked by GW6471, a PPARalpha antagonist, in a concentration-dependent manner.	GW 6471	56-62	peroxisome proliferator activated receptor alpha	Homo sapiens	66-75
21554872-8	2011	Pit-induced ABCA1 expression alteration was blocked by GW6471 (PPARalpha antagonist) and by PPARalpha knockdown.	GW 6471	55-61	ATP binding cassette subfamily A member 1	Homo sapiens	12-17
21554872-8	2011	Pit-induced ABCA1 expression alteration was blocked by GW6471 (PPARalpha antagonist) and by PPARalpha knockdown.	GW 6471	55-61	peroxisome proliferator activated receptor alpha	Homo sapiens	63-72
19150877-4	2009	The effects of simvastatin were prevented by the PPARgamma antagonist GW9662 or the PPARalpha antagonist GW6471.	GW 6471	105-111	peroxisome proliferator activated receptor alpha	Homo sapiens	84-93
21391669-8	2011	However, the above effects of ALA on platelets were markedly reversed by simultaneous addition of selective PPARalpha antagonist (GW6471) or PPARgamma antagonist (GW9662).	GW 6471	130-136	peroxisome proliferator activated receptor alpha	Homo sapiens	108-117
19150877-6	2009	The effects of fenofibrate were prevented by PPARalpha antagonism with GW6471.	GW 6471	71-77	peroxisome proliferator activated receptor alpha	Homo sapiens	45-54
20738325-8	2010	The selective PPARalpha antagonist GW6471 concentration-dependently decreased atrial natriuretic factor mRNA expression by 23%, 36%, 44% and 59%, and significantly decreased total RNA levels, protein synthesis and cell surface areas, all of which were elevated by 72h of leptin treatment.	GW 6471	35-41	peroxisome proliferator activated receptor alpha	Rattus norvegicus	14-23
20738325-8	2010	The selective PPARalpha antagonist GW6471 concentration-dependently decreased atrial natriuretic factor mRNA expression by 23%, 36%, 44% and 59%, and significantly decreased total RNA levels, protein synthesis and cell surface areas, all of which were elevated by 72h of leptin treatment.	GW 6471	35-41	natriuretic peptide A	Rattus norvegicus	78-103
20738325-8	2010	The selective PPARalpha antagonist GW6471 concentration-dependently decreased atrial natriuretic factor mRNA expression by 23%, 36%, 44% and 59%, and significantly decreased total RNA levels, protein synthesis and cell surface areas, all of which were elevated by 72h of leptin treatment.	GW 6471	35-41	leptin	Rattus norvegicus	271-277
20738325-9	2010	The augmentation of reactive oxygen species levels in leptin treated cardiomyocytes was reversed by 0.1-10mumol/L GW6471 (40%, 52% and 58%).	GW 6471	114-120	leptin	Rattus norvegicus	54-60
17439719-0	2007	Time-dependence of cardiomyocyte differentiation disturbed by peroxisome proliferator-activated receptor alpha inhibitor GW6471 in murine embryonic stem cells in vitro.	GW 6471	121-127	peroxisome proliferator activated receptor alpha	Mus musculus	62-110
17467307-6	2007	Application of PPARalpha antagonist GW6471 prevented cardiomyocyte differentiation as indicated by reduced expression of cardiac specific genes (alpha-MHC, MLC2v) and cardiac sarcomeric proteins (alpha-Actinin, Troponin-T).	GW 6471	36-42	peroxisome proliferator activated receptor alpha	Mus musculus	15-24
17467307-6	2007	Application of PPARalpha antagonist GW6471 prevented cardiomyocyte differentiation as indicated by reduced expression of cardiac specific genes (alpha-MHC, MLC2v) and cardiac sarcomeric proteins (alpha-Actinin, Troponin-T).	GW 6471	36-42	myosin, heavy polypeptide 6, cardiac muscle, alpha	Mus musculus	145-154
17467307-6	2007	Application of PPARalpha antagonist GW6471 prevented cardiomyocyte differentiation as indicated by reduced expression of cardiac specific genes (alpha-MHC, MLC2v) and cardiac sarcomeric proteins (alpha-Actinin, Troponin-T).	GW 6471	36-42	myosin, light polypeptide 2, regulatory, cardiac, slow	Mus musculus	156-161
17439719-3	2007	Cardiac specific genes and sarcomeric proteins were evaluated when embryoid bodies were challenged with PPAR alpha specific inhibitor GW6471 at different time courses.	GW 6471	134-140	peroxisome proliferator activated receptor alpha	Mus musculus	104-114
17439719-6	2007	The inhibition of PPAR alpha by its specific inhibitor GW6471 (1X10(-5) mol/L) significantly prevented cardiomyocyte differentiation and resulted in the reduced expression of cardiac sarcomeric proteins (ie alpha-actinin, troponin-T) and specific genes (ie alpha-MHC, MLC2v) in a time-dependent manner.	GW 6471	55-61	peroxisome proliferator activated receptor alpha	Mus musculus	18-28
17439719-6	2007	The inhibition of PPAR alpha by its specific inhibitor GW6471 (1X10(-5) mol/L) significantly prevented cardiomyocyte differentiation and resulted in the reduced expression of cardiac sarcomeric proteins (ie alpha-actinin, troponin-T) and specific genes (ie alpha-MHC, MLC2v) in a time-dependent manner.	GW 6471	55-61	myosin, heavy polypeptide 6, cardiac muscle, alpha	Mus musculus	257-266
17439719-6	2007	The inhibition of PPAR alpha by its specific inhibitor GW6471 (1X10(-5) mol/L) significantly prevented cardiomyocyte differentiation and resulted in the reduced expression of cardiac sarcomeric proteins (ie alpha-actinin, troponin-T) and specific genes (ie alpha-MHC, MLC2v) in a time-dependent manner.	GW 6471	55-61	myosin, light polypeptide 2, regulatory, cardiac, slow	Mus musculus	268-273
34522714-4	2021	The enhanced ADAM10 transcription by sulfuretin was mediated by the nucleotides -444 to -300 in the promoter region, and was attenuated by silencing or mutation of transcription factor retinoid X receptor (RXR) and by GW6471, a specific inhibitor of peroxisome proliferator-activated receptor alpha (PPAR-alpha).	GW 6471	218-224	ADAM metallopeptidase domain 10	Homo sapiens	13-19
34984327-5	2022	We found that chemical probe GW6471 is a potent, dual PPARalpha/gamma antagonist with anti-invasive and anti-proliferative activity in vitro.	GW 6471	29-35	peroxisome proliferator activated receptor alpha	Mus musculus	54-63
34867358-8	2021	The effects of (+)-dehydrovomifoliol were partially reversed by treatment with the PPARalpha antagonist GW6471, indicating the important role of the PPARalpha-FGF21 axis in the effects of (+)-dehydrovomifoliol.	GW 6471	104-110	peroxisome proliferator activated receptor alpha	Homo sapiens	83-92
34867358-8	2021	The effects of (+)-dehydrovomifoliol were partially reversed by treatment with the PPARalpha antagonist GW6471, indicating the important role of the PPARalpha-FGF21 axis in the effects of (+)-dehydrovomifoliol.	GW 6471	104-110	peroxisome proliferator activated receptor alpha	Homo sapiens	149-158
34867358-8	2021	The effects of (+)-dehydrovomifoliol were partially reversed by treatment with the PPARalpha antagonist GW6471, indicating the important role of the PPARalpha-FGF21 axis in the effects of (+)-dehydrovomifoliol.	GW 6471	104-110	fibroblast growth factor 21	Homo sapiens	159-164
34380243-7	2021	In nude mice, MEHP exposure significantly promoted the metastasis of ovarian cancer xenografts, which could be suppressed by the treatment of PPARalpha inhibitor GW6471.	GW 6471	162-168	peroxisome proliferator activated receptor alpha	Mus musculus	142-151
11845213-4	2002	Here we report the crystal structure of a ternary complex containing the peroxisome proliferator-activated receptor-alpha ligand-binding domain bound to the antagonist GW6471 and a SMRT co-repressor motif.	GW 6471	168-174	peroxisome proliferator activated receptor alpha	Homo sapiens	73-121
11845213-4	2002	Here we report the crystal structure of a ternary complex containing the peroxisome proliferator-activated receptor-alpha ligand-binding domain bound to the antagonist GW6471 and a SMRT co-repressor motif.	GW 6471	168-174	nuclear receptor corepressor 2	Homo sapiens	181-185
34216172-13	2021	GW6471 (a PPARalpha inhibitor) and cPLA2-inhalpha inhibited NO synthesis stimulated by ACh.	GW 6471	0-6	peroxisome proliferator activated receptor alpha	Homo sapiens	10-19
34092291-5	2021	To clarify the contribution of peroxisome proliferator-activated receptor alpha (PPARalpha), PPARalpha antagonist GW6471 was co-administrated with silybin to NAFLD mice.	GW 6471	114-120	peroxisome proliferator activated receptor alpha	Mus musculus	93-102
34092291-10	2021	GW6471 abolished the effect of silybin on PPARalpha signal and hepatoprotective effect against NAFLD.	GW 6471	0-6	peroxisome proliferator activated receptor alpha	Mus musculus	42-51
34522714-4	2021	The enhanced ADAM10 transcription by sulfuretin was mediated by the nucleotides -444 to -300 in the promoter region, and was attenuated by silencing or mutation of transcription factor retinoid X receptor (RXR) and by GW6471, a specific inhibitor of peroxisome proliferator-activated receptor alpha (PPAR-alpha).	GW 6471	218-224	peroxisome proliferator activated receptor alpha	Homo sapiens	250-298
34522714-4	2021	The enhanced ADAM10 transcription by sulfuretin was mediated by the nucleotides -444 to -300 in the promoter region, and was attenuated by silencing or mutation of transcription factor retinoid X receptor (RXR) and by GW6471, a specific inhibitor of peroxisome proliferator-activated receptor alpha (PPAR-alpha).	GW 6471	218-224	peroxisome proliferator activated receptor alpha	Homo sapiens	300-310
35354667-7	2022	GW6471, PPARalpha antagonist, and siRNA for PPARalpha suppressed telmisartan- and irbesartan-induced adiponectin secretion, suggesting that PPARalpha is the main target of these ARBs to increase adiponectin secretion in HWAs.	GW 6471	0-6	adiponectin, C1Q and collagen domain containing	Homo sapiens	101-112
35184357-11	2022	CONCLUSIONS: Our study unravels that the small-molecule compound GW6471 exerts an attractive therapeutic effect for CLA-induced HCL, involving multiple pathways with the "PPARalpha-RORgamma-SREBP2" being a potential complex player in this hepatic cholesterol biosynthesis programing.	GW 6471	65-71	sterol regulatory element binding factor 2	Mus musculus	190-196
35367313-13	2022	In addition, the GW6471 downregulated the expression of CREB, BDNF and other neurotrophins in SAE mice treated with H2.	GW 6471	17-23	cAMP responsive element binding protein 1	Mus musculus	56-60
35367313-13	2022	In addition, the GW6471 downregulated the expression of CREB, BDNF and other neurotrophins in SAE mice treated with H2.	GW 6471	17-23	brain derived neurotrophic factor	Mus musculus	62-66
35469820-8	2022	In order to evaluate the role of PPAR-alpha in the anti-inflammatory effect of PEA after ICH, the PPAR-alpha antagonist GW6471 was utilized.	GW 6471	120-126	peroxisome proliferator activated receptor alpha	Mus musculus	98-108
35421560-9	2022	The effects of phthalate metabolites on PPAR target genes were inhibited in most of the cultures by co-treatment with the PPAR-gamma inhibitor, T0070907, or with the PPAR-alpha inhibitor, GW6471.	GW 6471	188-194	peroxisome proliferator activated receptor alpha	Mus musculus	166-176
35546166-6	2022	Experiments using the PPARalpha inhibitor GW6471 or siRNA-mediated PPARalpha depletion showed that RV-mediated L1-RTP"s inhibition depended on peroxisome proliferator-activated receptor alpha (PPARalpha).	GW 6471	42-48	peroxisome proliferator activated receptor alpha	Homo sapiens	22-31
35546166-6	2022	Experiments using the PPARalpha inhibitor GW6471 or siRNA-mediated PPARalpha depletion showed that RV-mediated L1-RTP"s inhibition depended on peroxisome proliferator-activated receptor alpha (PPARalpha).	GW 6471	42-48	peroxisome proliferator activated receptor alpha	Homo sapiens	193-202
35370715-9	2022	PPARalpha agonist fenofibrate was able to mimic the cytoprotective effect of DCHT on intrahepatic cholestasis, which was abolished by the PPARalpha antagonist GW6471.	GW 6471	159-165	peroxisome proliferator activated receptor alpha	Homo sapiens	0-9
35460276-7	2022	The PPARalpha antagonist GW6471 improved obesity and NASH, dependent on intestinal PPARalpha or FABP1.	GW 6471	25-31	peroxisome proliferator activated receptor alpha	Mus musculus	4-13
35460276-7	2022	The PPARalpha antagonist GW6471 improved obesity and NASH, dependent on intestinal PPARalpha or FABP1.	GW 6471	25-31	peroxisome proliferator activated receptor alpha	Mus musculus	83-92
35460276-7	2022	The PPARalpha antagonist GW6471 improved obesity and NASH, dependent on intestinal PPARalpha or FABP1.	GW 6471	25-31	fatty acid binding protein 1, liver	Mus musculus	96-101
35460276-9	2022	Translationally, GW6471 reduced human PPARA-driven intestinal fatty acid uptake and improved obesity-related metabolic dysfunctions in PPARA-humanized, but not Ppara-null, mice.	GW 6471	17-23	peroxisome proliferator activated receptor alpha	Homo sapiens	38-43
35460276-9	2022	Translationally, GW6471 reduced human PPARA-driven intestinal fatty acid uptake and improved obesity-related metabolic dysfunctions in PPARA-humanized, but not Ppara-null, mice.	GW 6471	17-23	peroxisome proliferator activated receptor alpha	Homo sapiens	135-140
35370715-9	2022	PPARalpha agonist fenofibrate was able to mimic the cytoprotective effect of DCHT on intrahepatic cholestasis, which was abolished by the PPARalpha antagonist GW6471.	GW 6471	159-165	peroxisome proliferator activated receptor alpha	Homo sapiens	138-147
35059953-5	2022	Results from Western blotting showed that Ox-LDL induces the protein expression of both SULT1E1 and peroxisome proliferator-activated receptor (PPAR) gamma in human umbilical vein endothelial cells (HUVECs), and then that a PPARgamma antagonist GW9662, but not a PPARalpha antagonist GW6471, inhibited the protein expression of SULT1E1 induced by Ox-LDL.	GW 6471	284-290	sulfotransferase family 1E member 1	Homo sapiens	88-95
35059953-5	2022	Results from Western blotting showed that Ox-LDL induces the protein expression of both SULT1E1 and peroxisome proliferator-activated receptor (PPAR) gamma in human umbilical vein endothelial cells (HUVECs), and then that a PPARgamma antagonist GW9662, but not a PPARalpha antagonist GW6471, inhibited the protein expression of SULT1E1 induced by Ox-LDL.	GW 6471	284-290	peroxisome proliferator activated receptor gamma	Homo sapiens	100-155